Latest Industry Projects

Bharat Biotech launched clinically proven typhoid conjugate vaccine Typbar-TCV

projects

Bharat Biotech announced the launch of World’s first clinically proven typhoid conjugate vaccine Typbar-TCV™ , a fourth generation vaccine against typhoid disease, proven to provide long term protection to adults and infants 6 months & older. Currently available Typhoid vaccines fall short in two major characteristics, namely long term protection and protection for children below 2 years of age, the population that needs it the most. During its development since 2005 Typbar-TCV™ was evaluated in ~1200 healthy subjects at 9clinical sites. In the pivotal ph III clinical study, Typbar-TCV™ presented 98% seroconversion in infants aged 6 months to 24 months, 99% in children between 2 to 15 years of age, and 92% in the 15 to 45 year age group, as measured by 4 fold increase in serum IgG responses. It proved to be superior to the Vi polysaccharide typhoid vaccines. Typbar-TCV™ was also safe and well tolerated in all tested age groups. “Typhoid fever remains an important public health challenge in many countries of the world mainly because of poor diagnostics and increasing resistance to antibiotics. At present fundamental prevention strategies like improved sanitation, good hygienic practices and access to clean water are still out of reach for many impoverished communities. One of the most cost effective approaches to prevent infectious diseases, are vaccines which are available now and could help control the disease resulting in reduction of unnecessary suffering and adverse financial consequences.” Dr. Christian Loucq, M.D., Director-General of the International Vaccine Institute (IVI) said.Typhoid fever is a life threatening illness caused by the bacterium Salmonella typhi, which istransmitted through food or drink contaminated by the faeces or urine of infected people. Symptoms include high fever, malaise, headache, constipation, diarrhoea, etc. Healthy carrier state may follow acute illness. It causes between 250,000 to 600,000 deaths and 20 million illnesses per year, affecting mostly school-age children. The World Health Organization reports 90 percent of typhoid deaths occur in Asia and persists mainly in children under 5 years of age. In India, Typhoid fever is observed throughout the year and a greater number of cases coincide with the rainy season. While typhoid fever can be cured by antibiotics, resistance to antimicrobials is widespread along with poor diagnostics, hence prevention of typhoid fever is better than the cure. http://www.bharatbiotech.com/wp-content/plugins/prs/pdf/BBIL-TypbarTCV-Launch-PressRelease-26August2013-F1(1).pdf Project Name Bharat Biotech launched clinically proven typhoid conjugate vaccine Typbar-TCV Location India Commence 2013 Completion -NA- Estimated Investment -NA- Capacity -NA- Key Players Bharat Biotech

Other Projects